Opinion|Videos|July 29, 2024
Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the impact of dose modifications or interruptions on treatment outcomes with CDK4/6 inhibitors in the adjuvant setting?
- What has your experience been with toxicities and their management impacting patient adherence to CDK4/6 inhibitors in the adjuvant setting, and what strategies have you used to help improve this?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Novel Iberdomide Regimen in RRMM
2
Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD
3
AI Model Outperforms Apnea-Hypopnea Index in Predicting Sleep Apnea Mortality Risk
4
IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds
5